chufangao/CTO huggingface dataset:
Clinical trial NCT03925246: Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas
Official title: A Phase II Study From the POLA National Network of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas
Acronym: REVOLUMAB
Sponsor: Assistance Publique - Hôpitaux de Paris (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 43.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-07-30
Primary completion date: 2020-12-02
Completion date: 2021-08-18
Plan to share individual participant data: YES
IPD sharing description: Data are available upon reasonable request. The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients.~Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.
IPD time frame: Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor.
IPD access criteria: Researchers who provide a methodologically sound proposal.
Clinical trial NCT03801356: Threshold Response of Lumbar Selective Nerve Root Block in Predicting Good Outcome Following Lumbar Foraminotomy
Official title: Defining the Threshold Response of Lumbar Selective Nerve Root Block in Predicting Good Outcome Following Lumbar Foraminotomy
Sponsor: The Cleveland Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: The study was terminated early due to a number of concurrent issues: low enrollment, limited data and COVID-19.
Enrollment: 11.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-08-23
Primary completion date: 2020-11-05
Completion date: 2020-12-15
Limitations and caveats: The study was terminated early due to a number of concurrent issues. We found it difficult to enroll patients. Many of the patients were from out of region and/or had presented with a concurrent spinal injection. A new study injection could not be ordered due to the aforementioned issues. We attempted to mitigate, but it proved to be difficult.
Plan to share individual participant data: NO
Clinical trial NCT04361461: Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)
Official title: Hydroxychloroquine or Hydroxychloroquine Associated With Azithromycin for Inpatients With Moderate or Severe Lung Disease Due to SARS-CoV-2 (COVID-19)
Sponsor: Apsen Farmaceutica S.A. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: This study was canceled before enrollment due to a decision by the Sponsor
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-30
Primary completion date: 2020-11-04
Completion date: 2020-11-04
Plan to share individual participant data: NO
Clinical trial NCT04046549: A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant
Official title: A Phase 2a Single-arm, Prospective, Open-label Pilot Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant
Sponsor: Viela Bio (acquired by Horizon Therapeutics) (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 25.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-10-30
Primary completion date: 2022-07-18
Completion date: 2023-03-22
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02607488: Perioperative Systemic Lidocaine for Enhanced Bowel Recovery After Bariatric Surgery
Official title: Perioperative Systemic Lidocaine for Enhanced Bowel Recovery After Laparoscopic Bariatric Surgery: A Dose Dependent Study
Sponsor: Mansoura University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: SUSPENDED 
Why stopped: No fund no enough recruiting centers
Enrollment: 180.0 (ESTIMATED)
Number of arms: 4.0
Start date: 2020-11-30
Primary completion date: 2022-12-31
Completion date: 2023-02-28
Clinical trial NCT03361124: Oxytocin Dosing at Planned Cesarean Section and Anemia
Official title: Oxytocin Dosing at Planned Cesarean Section and Postpartum Anemia: A Comparison of Two Protocols
Sponsor: Milton S. Hershey Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Investigator no longer interested in proceeding with study
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-03-01
Primary completion date: 2020-03-01
Completion date: 2020-03-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05167513: Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients
Official title: Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients
Acronym: DQOL
Sponsor: Getz Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 188.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-01-01
Primary completion date: 2022-04-28
Completion date: 2022-04-28
Plan to share individual participant data: NO
IPD sharing description: Diabetes Quality of Life (DQOL) scores, HbA1c, Fasting Blood Sugars (FBS) (masking patients' identity)
Clinical trial NCT04000919: Effects of 5HTP and LDOPA on CNS Excitability After SCI
Official title: The Effects of 5-hydroxytryptophan (5-HTP) and L-3,4-dihydroxyphenylalanine (L-DOPA) Supplementation on Central Nervous System Excitability and Motor Function in Individuals With Spinal Cord Injury
Sponsor: University of Louisville (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: SUSPENDED 
Why stopped: PI left UofL and intends to reopen study at University of Alberta
Enrollment: 30.0 (ESTIMATED)
Number of arms: 4.0
Start date: 2019-06-19
Primary completion date: 2023-06-30
Completion date: 2023-12-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04435626: Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%
Official title: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Finerenone on Morbidity and Mortality in Participants With Heart Failure (NYHA II-IV) and Left Ventricular Ejection Fraction ≥ 40% (LVEF ≥ 40%)
Acronym: FINEARTS-HF
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 6016.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-14
Primary completion date: 2024-05-15
Completion date: 2024-06-14
Plan to share individual participant data: NO
IPD sharing description: Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA Principles for responsible clinical trial data sharing. This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.~Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Clinical trial NCT03918447: A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON
Official title: A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Autosomal Dominant Polycystic Kidney Disease
Acronym: FALCON
Sponsor: Biogen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Discontinuation of all bardoxolone chronic kidney disease programs
Enrollment: 667.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-05-29
Primary completion date: 2023-08-08
Completion date: 2023-08-08
Baseline population: Intent-to-Treat (ITT) population included all enrolled participants categorized by their randomized treatment group (whether or not they received study drug).
Limitations and caveats: Due to discontinuation of all bardoxolone chronic kidney disease programs, study was terminated early.
Plan to share individual participant data: YES
IPD sharing description: In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Clinical trial NCT02958865: Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis
Official title: A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY OF ORAL PF-06651600 AND PF-06700841 AS INDUCTION AND CHRONIC THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 319.0 (ACTUAL)
Number of arms: 10.0
Start date: 2017-02-03
Primary completion date: 2021-05-10
Completion date: 2021-05-10
Baseline population: All randomized participants who received at least 1 dose of PF-06651600, PF-06700841, or placebo.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT02261883: Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn
Official title: Intravenous Remodulin (Treprostinil) as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Randomized, Placebo-Controlled, Safety and Efficacy Study
Sponsor: United Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor Decision
Enrollment: 42.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-07-29
Primary completion date: 2022-09-27
Completion date: 2023-05-17
Baseline population: Intent-to-Treat Population
Clinical trial NCT02857010: Allogenic Bone Marrow Mesenchymal Stem Cell Therapy in Acute-on-chronic Liver Failure
Official title: Therapeutic Effects of Allogenic Mesenchymal Stem Cells in Cirrhotic Patients With Acute-on-chronic Liver Failure. A Double-blind Randomized Placebo-controlled Trial
Acronym: Liveradvance
Sponsor: Hospital Clinic of Barcelona (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Dificulties to recruit patients and dificulties to obtain MSCs.
Enrollment: 23.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-02-29
Primary completion date: 2018-02-28
Completion date: 2020-02-29
Plan to share individual participant data: YES
Clinical trial NCT03036150: A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease
Official title: A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease
Acronym: Dapa-CKD
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 4304.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-02-02
Primary completion date: 2020-06-12
Completion date: 2020-06-12
Plan to share individual participant data: NO
Clinical trial NCT04348656: CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)
Official title: A Randomized Open-Label Trial of CONvalenscent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1)
Acronym: CONCOR-1
Sponsor: McMaster University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study was terminated after the planned interim analysis as the pre-defined futility threshold was met
Enrollment: 940.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-14
Primary completion date: 2021-03-05
Completion date: 2021-06-16
Plan to share individual participant data: NO
Clinical trial NCT02792218: Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis
Official title: A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis
Acronym: ASCLEPIOS I
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 930.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-09-20
Primary completion date: 2019-07-05
Completion date: 2020-07-20
Limitations and caveats: This study was not powered for the analysis of some secondary endpoints as a stand-alone study. It was pre-specified in the study protocol to combine the data with study COMB157G2302 to address these endpoints.
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT02845414: Study of CD133KDEL Toxin in the Treatment for Solid Tumors
Official title: Phase I Study Of Stem-Cell Directed Deimmunized CD133KDEL Toxin In The Treatment Of Solid Tumors
Sponsor: Masonic Cancer Center, University of Minnesota (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Funding unavailable
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-12-31
Primary completion date: 2022-01-31
Completion date: 2022-01-31
Clinical trial NCT03989531: Adrecizumab in Cardiogenic Shock
Official title: Investigator-initiated, Placebo-controlled, Double-blind, Multi-center, Randomized Trial to Assess the Efficacy and Safety of Adrecizumab in Subjects With Cardiogenic Shock
Acronym: ACCOST-HH
Sponsor: Universitätsklinikum Hamburg-Eppendorf (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 150.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-04
Primary completion date: 2021-04-26
Completion date: 2021-04-26
Plan to share individual participant data: NO
Clinical trial NCT03481556: Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
Official title: An Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination With Either Bortezomib or Daratumumab in Patients With Relapsed or Relapsed-Refractory Multiple Myeloma
Acronym: ANCHOR
Sponsor: Oncopeptides AB (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The sponsor decided to terminate the study following an FDA request of a partial clinical hold.
Enrollment: 56.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-04-12
Primary completion date: 2022-02-02
Completion date: 2022-02-02
Baseline population: Participants included in the Safety Analysis Set were included in the Baseline Characteristics. The Safety Analysis Set includes all patients that have received at least 1 dose (or partial dose) of melflufen, dexamethasone, or partner therapy (bortezomib or daratumumab).
Limitations and caveats: On 04 November 2021, the study was terminated early during Phase 2a.
Plan to share individual participant data: NO
Clinical trial NCT04126031: Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.
Official title: A PHASE 2A, 2-PART, OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, SINGLE AND MULTIPLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF CEFTAZIDIME AND AVIBACTAM IN NEONATES AND INFANTS FROM BIRTH TO LESS THAN 3 MONTHS OF AGE WITH SUSPECTED OR CONFIRMED INFECTIONS DUE TO GRAM-NEGATIVE PATHOGENS REQUIRING INTRAVENOUS ANTIBIOTIC TREATMENT
Acronym: NOOR
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Following regulatory consultation, the Sponsor has decided to terminate the study and analyze the current dataset. The decision to terminate was solely based on a business decision, not due to safety concerns.
Enrollment: 48.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-14
Primary completion date: 2022-12-30
Completion date: 2022-12-30
Baseline population: Safety analysis sets for Part A and Part B included participants who received any amount of the investigational drug (CAZ-AVI) in the respective part.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT04456699: Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)
Official title: A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer Who Have Not Progressed Following First-line Induction (LYNK-003)
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 335.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-08-19
Primary completion date: 2023-03-27
Completion date: 2023-11-06
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT04632537: BCG Vaccination to Prevent COVID-19
Official title: Novel Use of an Existing Vaccine (BCG) Alliance: The NUEVA Trial
Acronym: NUEVA
Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Due to funding - project never enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-07
Primary completion date: 2021-03-23
Completion date: 2021-03-23
Plan to share individual participant data: NO
Clinical trial NCT03591575: Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children
Official title: Safety and Efficacy of Early-start Deferiprone Treatment in Infants and Young Children Newly Diagnosed With Transfusion-dependent Beta Thalassemia
Acronym: START
Sponsor: Chiesi Canada Corp (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 64.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-09
Primary completion date: 2020-09-29
Completion date: 2020-09-29
Clinical trial NCT03803202: A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine
Official title: A Phase 1/2, Randomized, Single Ascending Dose Study in Adults (Stage 1) and Randomized, Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, a Pneumococcal Vaccine
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 630.0 (ACTUAL)
Number of arms: 9.0
Start date: 2019-01-24
Primary completion date: 2020-09-28
Completion date: 2020-09-28
Plan to share individual participant data: YES
IPD sharing description: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.
IPD time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
IPD access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
Clinical trial NCT03449134: A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027)
Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants With Chronic Cough (PN027)
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 732.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-03-14
Primary completion date: 2020-06-05
Completion date: 2020-08-17
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT04016714: Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)
Official title: A Phase 3, Multicenter, Randomized, Double-blind, Active-comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2)
Acronym: PNEU-PED-EU-2
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1191.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-28
Primary completion date: 2021-10-29
Completion date: 2021-10-29
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf